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Background: The multifactorial control of diabetes relies on interventions that provide patients with the best
knowledge and resources available. The objective of this research was to analyze the clinical characteristics of a
sample of people with type 2 diabetes at high cardiovascular risk, and establish possible links between disease
control, family history and lifestyle, to improve the quality of interventions. Family history, lifestyle habits,
blood pressure, anthropometric data and laboratory tests were analyzed in this descriptive and comparative
cross-sectional study.
Results: All patients had a pathological body mass index (BMI), and in those patients with a family history of
diabetes, the disease was more serious and onset was earlier. Overall, 70.9% were taking drugs for arterial blood
pressure management, with mean values within recommended limits; 87.1% were taking antihyperlipidemic drugs
and had mean values for blood lipids within reference range; 93.5% were receiving oral antidiabetic drugs and/or
insulin and had blood glucose and glycosylated hemoglobin (HbA1c) values higher than recommended limit; and
87% were taking antiplatelet drugs and had fibrinogen and ultrasensitive C-reactive protein higher than the normal
range. High HbA1c values were found in a high proportion of our sample who were not following a tailored diet
(84.2%), and better BMIs were associated with moderate physical activity. Coexistence of somatic disorders (97.4%
of the sample with musculoskeletal diseases) could lead to the lack of physical activity.
Conclusions: This sample of patients with type 2 diabetes and at high cardiovascular risk, had acceptable
metabolic control, facilitated by drug therapy. Family history of diabetes was associated with earlier disease onset
and worse disease progression. Patients who were not following a tailored diet had worse HbA1c values compared
with those who were. Individuals who practiced moderate physical activity in line with international
recommendations for weight maintenance had the best BMI values, but the high prevalence of comorbidities could
adversely affect exercise habits. Appropriate use of medication, dietary advice, and tailored physiotherapy physical
activity suitable for people with comorbidities should be included in multifactorial treatment strategies for these
patients, particularly in the presence of a family history of diabetes.
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Table 1 General sample characteristics
General characteristics
of the sample
Percentage or mean ± SD
[95% CI]
Females 74% (n = 28)
Males 26% (n = 10)
Age (years) 59.1 ± 7.6 [56.6-61.6]
Age at the onset of diabetes (years) 48.7 ± 10.2 [45.4-52.1]
Family history of diabetes 70% (n = 26)
Adapted diet in the last 12 months 15.8% (n = 6)
Smoking habit 0% (n = 0)
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Diabetes mellitus is currently a major public health
problem [1]. In 2011, 366 million people worldwide were
estimated to have diabetes. In Europe in 2011, 52.8 mil-
lion people between 20 and 79 years of age had diabetes,
with a prevalence of 8.1% [2]. In Spain between 2004
and 2010, 13.8% of people aged 18 and over had dia-
betes, similar to 2004–2006 rates, with a high rate (43%)
of undiagnosed diabetes [3]. In Europe, one in 10 deaths
in those aged between 20 and 79 years can be attributed
to diabetes, with the vast majority of cases occurring in
people over 50 years of age [1]. The causes of this high
prevalence are attributable to both lifestyle and genetic
factors. In terms of genetic factors, at least 40 loci asso-
ciated with diabetes have been identified [4] and it has
been reported that approximately 40% of people with
type 2 diabetes have at least one relative that also has
the disorder [5].
Diet and exercise are the lifestyle habits with the great-
est influence on diabetes. In low- and middle-income
countries – areas with a higher prevalence of the disease –
the nutritional quality of food may be low, food with a
very high glycemic index is consumed [6], and very little
physical activity is done, because of technological ad-
vances and the lack of time. Therefore, control of this
disease is a global health challenge and great efforts
have been made in all health sciences fields to intervene
in the process and to try to reverse it.
Recent studies published in Spain about the treatment




With family history of
diabetes (n = 26)
Mean ± SD/power value
Age at the onset of diabetes 45 ± 7.9/0.9
Weight 89.6 ± 13.5/0.9
Waist circumference 110.1 ± 11.4/0.9
Total cholesterol 176.3 ± 19.9/0.8
Glucose 149.3 ± 42.6/0.7risk factors show encouraging results. In 2007, Orozco
and colleagues found below-baseline values for glycosyl-
ated hemoglobin (HbA1c) in 50.6% of the population,
blood pressure (BP) in 7.8% and low-density lipoprotein
(LDL)-cholesterol in 5.9% [7]. Data published by Franch
and collaborators in 2010 show a higher prevalence of
below-baseline levels of these variables (59%, 28.51%,
and 40.7% for HbA1c, BP and LDL-cholesterol, respect-
ively) [8]. Mengual and colleagues reported similar find-
ings in research published in 2010 (54.8%, 29.6%, and
40.6% for HbA1c, BP and LDL-cholesterol, respectively)
[9]. Taken together, these show positive results in the
treatment of diabetes mellitus, although it is necessary
to study larger populations of people with diabetes, in
line with levels recommended by reference scientific
societies.
Multifactorial control of cardiovascular risk factors is
important in achieving positive results. In the Steno
study [10], intensive treatment for all cardiovascular risk
factors, consisting of intensive drug therapy (antioxidant
vitamins and insulin, lipid-lowering, antihypertensive
and antiplatelet treatments), a low fat diet (<30% fat),
and exercise, over a period of 13 years was shown to
reduce complications by 29% and mortality by 20%.
The complexity of this intensive and multifactorial
control of diabetes [11] and the improved health and in-
creased survival that can be achieved, highlight the im-
portance of interventions that provide the patient with
the best knowledge and resources available [12].
The objective of this research was to analyze the clin-
ical characteristics of a sample of people with type 2
diabetes at high cardiovascular risk, and establish pos-
sible links between disease control, family history, and
lifestyle, to improve the quality of interventions.Methods
Study and sample selection
A descriptive and comparative cross-sectional study
was developed, comprising a sample of 38 people with
type 2 diabetes and a pathological body mass index (BMI)
who attended a specialized Endocrinology and NutritionWithout family history of
diabetes (n = 12) p value
Mean ± SD/power value
56.3 ± 10.8/0.7 0.002
77.9 ± 14/0.5 0.019
99.9 ± 11.2/0.6 0.026
160.2 ± 28.6/0.3 0.031
120.2 ± 27.1/0.7 0.045
Table 3 Cardiovascular risk parameters
Cardiovascular risk
components Values in the sample mean ± SD [95% CI] Reference values
Percentage values of the sample
within reference
BMI 34.8 ± 5.8 [32.9-36.7] 18.5-24.91 0% (n = 0)
Weight (kg) 85.5 ± 14.9 [80.6-90.4]
Waist circumference (cm) 106.7 ± 12.2 [102.7-110.7] < 88 females/102 males2 5.3% (n = 2) females/13.2% (n = 5) males
SBP (mmHg) 133.6 ± 13.8 [128.4-138.9] < 1401 47.4% (n = 18)
DBP (mmHg) 79.3 ± 5.9 [7781.–6] < 901 68.4% (n = 26)
Glucose (mg/dl) 141.3 ± 40.7 [127.5-155] < 1003 11.1% (n = 4)
Total cholesterol (mg/dl) 171.9 ± 23.4 [164180]– < 2001 91.7% (n = 33)
HDL-c (mg/dl) 56.8 ± 11 [5360.–5] > 501 66.7% (n = 24)
LDL-c (mg/dl) 92.1 ± 20.7 [85.2-99.1] < 1301 89.5% (n = 34)
Triglycerides (mg/dl) 123.1 ± 76.7 [97.2-149] < 2001 91.7% (n = 33)
HbA1c (%) 6.8 ± 1.3 [6.3-7.2] < 7%
3 44.7% (n = 17)
Fibrinogen (mg/dl) 339.3 ± 85.8 [309.8-368.8] 200-4004 77.1% (n = 27)
us-CRP (mg/L) 6.3 ± 7.4 [3.8-8.8] < 31 44.7% (n = 17)
1SEEDO 2007, 2ATP III 2002, 3ADA 2012, 4Gailani D, Neff AT 2008.
ADA = American Diabetes Association; ATPIII: adult treatment panel III; BMI = body mass index; HbA1c = glycosylated hemoglobin; HDL-c = high-density lipoprotein
cholesterol; LDL-c = low-density lipoprotein cholesterol; SEEDO = Spanish Society for the Study of Diabetes and Obesity; us-CRP = ultrasensitive C reactive protein.
Table 4 Medications used
Type of drug Percentage of the sample
Drugs to control blood pressure 70.9% (n = 27)
Hypolipidemic drugs 87.1% (n = 33)
Oral antidiabetic and/or insulin 93.5% (n = 36)
Antiplatelet drugs 87% (n = 33)
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Covian Specialty Medical Center) in Zaragoza, Spain.
Inclusion criteria were as follows: diagnosis of type 2
diabetes, according to the American Diabetes Associ-
ation (ADA) 2012 criteria [13]; diabetes duration >10
years; BMI ≥25; and age >45 years.
The Spanish Society for the Study of Diabetes and
Obesity (SEEDO) defines pathological BMI as follows:
overweight grade I, 25.0–26.9 kg/m2; overweight grade II
(pre-obesity), 27.0–29.9 kg/m2; obesity type I, 30.0–34.9
kg/m2; obesity type II, 35.0 to 39.9 kg/m2; obesity type
III (morbid), 40.0–49.9 kg/m2; and obesity type IV (ex-
treme) ≥50 kg/m2 [14].
All patients who met the inclusion criteria and
attended consultations were included. They voluntarily
accepted to participate after receiving information on
the study, so we used a convenience, consecutive, non-
probabilistic sampling method. All participants signed
an informed consent form and were told that they
could leave the study at any time and for any reason.
The Department of Physical Therapy and Nursing
at the University of Zaragoza approved the study,
which complied with the ethical requirements of the
Declaration of Helsinki [15].
Measurements
Medical histories for each patient were taken including
sex, age, age at diabetes onset, family history [16], co-
morbidities, diet in the past year, physical activity, smok-
ing status, and medication use.
The measurement of systolic blood pressure (SBP)
and diastolic blood pressure (DBP) was performed
using a sleeve adapted to obese patients [17] after aperiod of approximately 15 minutes in a sitting pos-
ition, with one tube and a clock tensiometer (Riester,
Jungingen, Germany).
Anthropometric data were obtained according to the
protocol of the International Society for the Advancement
of Kinanthropometry (ISAK) [18]. Height was measured
with a wall stadiometer (removable stadiometer, scope 30–
220 cm, Seca, Hamburg, Germany,), weight with an
electronic scale (Tanita TBF 300, Tanita, Amsterdam, the
Netherlands) and waist circumference with an inextensible
tape (plastic tape, 0–2 m, Tecsymp Instruments, Barcelona,
Spain).
The assessment of blood parameters was performed in
the laboratory of Grande Covian Specialty Medical Cen-
ter, by drawing blood after a fasting period of not less
than 12 hours. Biochemical analyses took place at the
Grande Covián laboratory. Total cholesterol, (HDL)-
cholesterol, (LDL)-cholesterol, triglycerides and fibrino-
gen were determined by nephelometry (Dade Behring
Corporation, Berlin, Germany). Fating blood glucose,
HbA1c, and ultrasensitive C reactive protein (us-CRP) were
determined using a selective modular analyzer (Roche,
Basel, Switzerland). Accreditation National Entity (ENAC)
validated the quality control of the laboratory (accreditation
number: 742/LE1586).
Table 5 Comparison according to having followed or not










HbA1c 5.85 ± 0.87/0.5 6.96 ± 1.31/0.9 0.037
HbA1c = glycosylated hemoglobin.
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Data were analyzed with SPSS version 16.0 (SPSS Inc.,
Chicago, USA). Descriptive statistics were calculated
(the mean and standard deviation (SD) and 95% confi-
dence interval (CI) for quantitative variables and per-
centages for qualitative variables).
We evaluated the magnitude of the association be-
tween quantitative variables with Spearman’s correlation
coefficient (rho).
The Mann–Whitney U test was used for the com-
parison of independent variables, which included
family history of diabetes (yes/no), dietary habits (no
diet/diet adapted to the clinical situation), and physical
activity (no physical activity/moderate physical activ-
ity). The power of these tests was calculated with the
effect size detected in the study. A level of significance
of 5% (p <0.05) was established to reject the null
hypothesis.Results
General characteristics of the sample are shown in
Table 1.
When stratified according to family history of diabetes,
there were significant differences in age of diabetes
onset, weight, waist circumference, total cholesterol,
and fasting blood glucose (Mann–Whitney U test). See
Table 2.
Descriptive data on cardiovascular risk components
are shown in Table 3 and drug prescriptions in Table 4.Figure 1 Dedication to physical activity.Of the study sample, 93.5% were taking drugs to control
blood glucose (41.9% were treated with oral agents, 6.4%
with insulin and 45.2% with oral agents associated with
insulin).
Only 15.8% of people were on a diet tailored to their
clinical condition (Table 1). When comparing this group
with the group that did not diet, differences in HbA1c
values were observed (Mann–Whitney U test). See
Table 5.
The type of physical activity undertaken is shown in
Figure 1. There was a statistically significant difference
in BMI between individuals who undertook moderate
physical activity compared with those who did not (p =
0.032) (Table 6).
The percentages of patients with coexisting somatic
disorders and sources of disability are shown in Figure 2.
Table 7 shows the correlation between various clinical
variables.
Discussion
This study included 38 people aged over 45 years with
type 2 diabetes of >10 years duration. Almost three-
quarters of the sample were female, and 70% had a fam-
ily history of diabetes. This proportion was slightly
higher than that outlined by previous studies provide
data on approximately 40% [5]. The age of onset of dia-
betes in our study was greater by approximately 11 years
in patients with a family history of diabetes compared
with the patients without a family history of diabetes. A
family history of diabetes negatively influenced weight,
waist circumference, blood glucose levels and cholesterol
levels. These results suggest the importance of the gen-
etic component in the pathogenesis of this process
[19,20] although it is known that environmental factors
also play an important role [21].
The mean BMI in our study was 34.81 kg/m2, and fat
distribution was central, with a high percentage of the
sample having a waist circumference higher than reference




Not physical activity (n = 14) Moderate physical activity (8 h/sem) (n = 22)
P value
Mean ± SD/power value Mean ± SD/power value
BMI 37.7 ± 5.8/0.4 33.7 ± 5.2/0.7 0.032
BMI = body mass index.
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ciated with increased cardiovascular risk, dyslipidemia and
insulin resistance [23]. In this study, people with larger
waist circumference had higher blood glucose, triglycer-
ides, LDL cholesterol and us-CRP, supporting the import-
ance of the loss of fat mass to facilitate the treatment of
type 2 diabetes [24].
Regarding concomitant drug use, 70.9% of our patients
were receiving drugs to control blood pressure, and
47.4% and 68.4% of study participants had SB, and DBP,
respectively, within the normal range. [14]. The positive
effects of blood pressure control in the course of the dis-
ease may have prevented the development of diabetic
nephropathy, as none of the patients showed this com-
plication, despite having been diagnosed with diabetes
for a long period of time [25].
A total of 87.1% of the sample was receiving lipid-
lowering therapy, and 91.7%, 66.7%, 89.5% and 91.7% of
patients had total cholesterol, HDL-cholesterol, LDL-
cholesterol and triglycerides below the recommended
levels [26].
By contrast, despite therapy with oral antidiabetic
drugs and/or insulin, in 93.5% of patients, the mean
blood glucose level was above target values. However,
44.7% had HbA1c below the target value of 7% (53
mmol/mol) [13,27]. Eighty-seven per cent of the sample
were receiving antiplatelet drug treatment, achieving a
mean fibrinogen value of 339.3 mg/dL, with 77.1% of the
sample having values below baseline [28].
Analysis of fibrinogen as a sensitive indicator of in-
flammation [29] can be complemented with the analysis
of the us-CRP, for which values in our study were higherFigure 2 Other somatic disorders.than reference values [25], and only 44.7% of subjects
were within the recommended levels. This observed
pro-inflammatory state might be related to insulin resist-
ance, because it has been demonstrated that the plasma
us-CRP might be a marker of risk for the development
of macrovascular disease and diabetes mellitus, even in-
dependently of obesity [30].
These data reflect that patients had acceptable meta-
bolic control according to ADA [31] and International
Diabetes Federation (IDF) [32] criteria, although the
pro-inflammatory markers indicate that this sample was
at high cardiovascular risk. The current clinical evidence
and consensus recommendations support that type 2
diabetes is associated with high cardiovascular risk, par-
ticularly when other risk factors are present, and at 10
years after diagnosis [22,30].
High HbA1c values were found in a high proportion of
our sample who were not following a tailored diet
(84.2%) [33], in agreement with recent studies that con-
tinue to show the benefits of the adjustments in diet to
control glucose metabolism [34-36].
Another key aspect of the treatment of diabetes is
physical activity [37]. A recent study has shown that
higher levels of physical activity are associated with de-
creased risk of developing diabetes, even independently
of the general and abdominal fat percentage [38]. In our
study, 57% of patients reported undertaking moderate
physical activity, at an average duration of 8 hours per
week, which is sufficient for the maintenance of weight
loss in obese people according to international recom-
mendations [39]. However, up to 37% reported under-
taking no physical activity, and when comparing the two






Age at the onset of diabetes (−) 0.375*
BMI 0.407* 0.397* 0.345*
Weight 0.427** 0.528** 0.350* 0.464** 0.395*
Waist circumference 0.371* 0.413* 0.444** 0.401*
Triglycerides 0.375* 0.368*
**Correlation is significant at the 0.01 level (bilateral). *Correlation is significant at the 0.05 level (bilateral).
BMI = body mass index; LDL-c = low-density lipoprotein cholesterol; us-CRP = ultrasensitive C reactive protein.
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the physically active group, as has been reported by
others [40].
One barrier to patients with diabetes undertaking
physical activity is the high prevalence of coexisting
conditions that may limit their functional ability and
cause alterations in sensitivity [41]. In the United States,
30% of people with type 2 diabetes have impaired sensa-
tion in the feet, and over 50% have osteoarthritis [42].
In our sample, up to 97.4% had musculoskeletal disor-
ders, including osteoarthritis, 7.9% had diabetic neur-
opathy and 7.9% had vascular complications, which may
have decreased adherence to physical activity because of
pain and decreased function. To facilitate exercise in
patients with such problems, exercise must be adapted
to the clinical situation and, ideally, treated specifically.
Reinforcing this, a recent study has demonstrated the
effectiveness of a physiotherapy exercise program for
patients with diabetes, with good results in controlling
pain and improving mobility [43].
A limitation to our study is that patients joined
the study voluntarily, leading to the possibility of
non-response bias on the part of the population that
would not, or could not, be included. The strict in-
clusion criteria of the study prevented the recruit-
ment of a larger sample size, which would have
improved the possibilities to estimate the true popula-
tion values, and larger studies in similar populations
are needed to confirm our findings.
Conclusions
This sample of patients, at high cardiovascular risk and
with a strong influence of a family history of diabetes,
had acceptable metabolic control, facilitated by inten-
sive drug therapy. Family history of diabetes was associ-
ated with earlier onset and worse disease progression.
Patients who were not following a tailored diet had
worse HbA1c values compared with those who were.
The proportion of the sample that practiced moderate
physical activity in line with international recommenda-
tions for weight maintenance had the best BMI values,
but the high prevalence of comorbidities could adverselyaffect exercise habits. Appropriate use of medication, diet-
ary advice, and tailored physiotherapy physical activity
suitable for people with comorbidities should be included
in multifactorial treatment strategies for these patients,
particularly in the presence of a family history of diabetes.Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article.
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